Immunomodulation of proteoglycan-induced progressive polyarthritis by lefluflomide
- 4 March 1992
- journal article
- Published by Elsevier in Immunopharmacology
- Vol. 23 (2) , 105-116
- https://doi.org/10.1016/0162-3109(92)90034-a
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejectionInflammation Research, 1991
- Proteoglycan‐induced polyarthritis and spondylitis adoptively transferred to naive (nonimmunized) BALB/c miceArthritis & Rheumatism, 1990
- Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritisInflammation Research, 1990
- Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in ratsInternational Journal of Immunopharmacology, 1989
- Cartilage proteoglycans as potential autoantigens in humans and in experimental animalsInflammation Research, 1988
- The use of the murine chronic graft Vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discoveryInflammation Research, 1987
- Disease modifying activity of HWA 486 in rat adjuvant-induced arthritisInflammation Research, 1987
- Disease modifying activity of HWA 486 on the development of SLE in MRL/1-miceInflammation Research, 1986
- Immunopharmacological profile of HWA 486, a novel isoxazol derivative— II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin AInternational Journal of Immunopharmacology, 1986
- Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity — I. Disease modifying action on adjuvant arthritis of the ratInternational Journal of Immunopharmacology, 1985